PharmaMar Victory Has EU Regulators Pondering Next Move
Top EU Court Says Filing For Multiple Myeloma Drug Was Wrongly Rejected
Executive Summary
PharmaMar’s persistence has paid off in its fight to overturn the European Commission’s rejection of its marketing application for the multiple myeloma drug, Aplidin.
You may also be interested in...
PharmaMar’s Aplidin In The Spotlight Again As Top EU Court Sets Aside Earlier Ruling On Approval
The Court of Justice says that the General Court was wrong to consider two experts from a university hospital as employees of a pharmaceutical company solely because the hospital housed a cell therapy research center.
Spanish Biotechs Join Battle Against COVID-19
Spain has suffered more than most from COVID-19 but the life sciences sector is exploring a variety of ways to tackle the coronavirus pandemic.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.